Mandate

Vinge advises MultiQ International AB on the acquisition of Public Systems Nordic AB

September 04, 2013

Vinge advises MultiQ International AB, listed on Nasdaq OMX Small Cap, in connection with the acquisition of Public Systems Nordic AB and the SEK 15m new issue of shares with preferential rights conducted in connection with the acquisition. Through the acquisition, Sweden’s largest company within monitor solutions for public spaces, so called Digital Signage, is created. The purchase price for the acquisition of Publiq is paid through the issuance of new shares in MultiQ.

The Vinge team advising MultiQ International AB includes partner Jesper Ottergren and, among others, associates Marcus Bergdahl and Christian Lindhé. Further, partner Erik Sjöman provides advice on capital markets regulations and Ingela Malmborg provides employment law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024